奈达铂或顺铂分别联合紫杉醇同步放疗用于中晚期宫颈癌的疗效比较  

Comparison of Clinical Observation of Nedaplatin or Cisplatin Combined with Paclitaxel Plus Chemoradiotherapy for Patients with Middle-advanced Uterine Cervical Cancer

作　　者：王昕雯[1] 高迎春[1] 

机构地区：[1]南京医科大学附属淮安第一医院,江苏淮安223300

出　　处：《中国药房》2017年第3期318-320,共3页China Pharmacy

摘　　要：目的:观察奈达铂或顺铂分别联合紫杉醇同步放疗用于中晚期宫颈癌的临床疗效和安全性。方法:120例中晚期宫颈癌患者随机分为观察组(60例)和对照组(60例)。观察组患者给予注射用奈达铂20 mg/m^2静脉滴注+紫杉醇注射液35 mg/m^2静脉滴注,每周1次;对照组患者给予注射用顺铂20 mg/m^2静脉滴注+紫杉醇注射液35 mg/m^2静脉滴注,每周1次。两组患者均予以同步放射治疗,先予以全盆腔放射治疗1.8~2.0 Gy/次,每日1次,每周5次,然后进行盆腔视野外放射治疗1.8~2.0 Gy/次,每日1次,每周4次。1周为1个疗程,两组均治疗6周。观察两组患者近期疗效、2年生存率、2年局部控制率和不良反应发生率。结果:治疗后,观察组患者有效率、2年生存率、2年局部控制率显著高于对照组,骨髓抑制发生率显著低于对照组,差异均有统计学意义(P<0.05);两组患者消化道反应、肝肾功能损害、脱发以及周围神经炎等不良反应发生率比较,差异无统计学意义(P>0.05)。结论:奈达铂联合紫杉醇同步放化疗用于中晚期宫颈癌的近期疗效、2年生存率、2年局部控制率优于顺铂联合紫杉醇,安全性方面两者相当,但前者较少发生骨髓抑制。OBJECTIVE： To observe the clinical efficacy and safety of nedaplatin or cisplatin combined with paclitaxel plus chemoradiotherapy for middle-advanced uterine cervical cancer. METHODS： 120 patients with middle-advanced uterine cervical can- cer were divided into observation group （60 cases） and control group （60 cases） by random. Observation group received nedaplatin 20 mg/m^2 by intravenous infusion＋paclitaxel 35 mg/m^2 by intravenous infusion, once a week, control group received cisplatin 20 mg/m^2 by intravenous infusion＋paclitaxel 35 mg/m^2 by intravenous infusion, once a week, 2 groups also received radiation therapy first radiation therapy in whole pelvic by 1.8-2.0 Gy/times, once a day, 5 times every week, then in pelvic outside by 1.8-2.0 Gy/ times, once a day, 4 times every week. And 2 groups were treated for 6 weeks. The short-term efficacy, 2-year survival rate, local control rate and the incidence of adverse reactions in 2 groups were observed. RESULTS： After treatment, the effective rate, 2-year survival rate and local control rate in observation group were significantly higher than control group, bone marrow suppres- sion rate was significantly lower than control group, with statistical significance（P〈0.05） ; there were no significant differences in the incidences of digestive tract reaction, liver and kidney function damage, hair loss, peripheral neuritis and other adverse reac- tions in 2 groups （P〉0.05）. CONCLUSIONS： Nedaplatin combined with paclitaxel plus chemoradiotherapy has good short-term efficacy, 2-year survival rate and local control rate for middle-advanced uterine cervical cancer than cisplatin combined with paclitax- el plus chemoradiotherapy, and little incidence of bone marrow suppression.

关 键 词：宫颈癌 同步放化疗 奈达铂 顺铂 紫杉醇 疗效 安全性 

分 类 号：R737.33[医药卫生—肿瘤]